MODULATION OF GALLBLADDER CONTRACTION BY PIRENZEPINE IN HUMANS


YEGEN B., BIREN T., ONAT F., TANKURT E., GURMEN N., OKTAY S., ...Daha Fazla

AMERICAN JOURNAL OF GASTROENTEROLOGY, cilt.90, sa.9, ss.1489-1494, 1995 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 90 Sayı: 9
  • Basım Tarihi: 1995
  • Dergi Adı: AMERICAN JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1489-1494
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objectives: The mechanism(s) by which cholinergic innervation modulates gallbladder contraction are not fully understood, To elucidate the role of muscarinic M(1) receptors in the mediation of gallbladder contraction, we investigated gallbladder volume reduction, plasma cholecystokinin (CCK), and pancreatic polypeptide (PP) responses in humans during cephalic and intestinal phases of a meal under M(1) muscarinic receptor blockade with pirenzepine. Methods: In eight healthy subjects, intraduodenal meal- and in seven subjects, sham feeding-induced gallbladder volume reduction was measured by real-time ultrasonography during saline or pirenzepine administration, Plasma CCK and PP were measured by radioimmunoassay, Results: Pirenzepine partially inhibited gallbladder volume reduction in response to an intraduodenal fatty meal, The integrated gallbladder volume reduction over 120 min was 4462 +/- 445%.min compared with 6879 +/- 279%.min in the saline control group (p < 0.01), Integrated plasma CCK and PP responses were unchanged in the presence of pirenzepine, Pirenzepine abolished sham feeding-induced gallbladder contraction and plasma PP response, Sham feeding with either isotonic saline or pirenzepine infusion did not modify fasting plasma CCK levels, Conclusion: M(1) muscarinic receptors play an important role in the intestinal and cephalic phases of gallbladder contraction, Plasma CCK response to intraduodenal meal is not influenced by M(1) muscarinic receptor blockade with pirenzepine.